Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function

• Published in: Journal of cardiac failure Vol. 16; no. 1; pp. 25 - 35
• Main Authors: Weatherley, Beth Davison, Cotter, Gad, Dittrich, Howard C, DeLucca, Paul, Mansoor, George A, Bloomfield, Daniel M, Ponikowski, Piotr, O'Connor, Christopher M, Metra, Marco, Massie, Barry M
• Format: Journal Article
• Language: English
• Published: United States 01.01.2010
• Subjects: Adenosine A1; Adenosine A1 Receptor Antagonists; Dermatologi och venereologi; Dermatology and Venereal Diseases; Double-Blind Method; drug effects; drug therapy; Female; Heart Failure; Heart Failure - drug therapy; Heart Failure - physiopathology; Hospitalization; Humans; Kidney Function Tests; Kidney Function Tests - methods; Kidney Function Tests - trends; Male; methods; pharmacology; physiology; physiopathology; Pilot Projects; Receptor; Receptor, Adenosine A1 - physiology; Stroke Volume; Stroke Volume - drug effects; Stroke Volume - physiology; therapeutic use; Treatment Outcome; trends; Xanthines; Xanthines - pharmacology; Xanthines - therapeutic use
• ISSN: 1071-9164; 1532-8414; 1532-8414
• DOI: 10.1016/j.cardfail.2009.10.025

Current treatment for acute decompensated heart failure (ADHF) is associated with incomplete resolution of symptoms and signs, recurrent symptoms of heart failure in-hospital and after discharge and high mortality. Studies have consistently demonstrated an association between worsening renal function in ADHF and adverse outcomes. Adenosine A(1) receptor antagonists, such as rolofylline, appear in preliminary studies to produce potentially beneficial effects on natriuresis, diuresis, renal blood flow, and glomerular filtration rate. In a previous dose-finding study, rolofylline 30 mg intravenously daily for 3 days was associated with symptom improvement, less worsening of renal function, and trends toward lower 60-day rates of death or readmission for cardiovascular or renal causes. This manuscript describes the rationale underlying the design of the phase 3 PROTECT (Placebo-controlled Randomized study of the selective A(1) adenosine receptor antagonist rolofylline for patients hospitalized with acute heart failure and volume Overload to assess Treatment Effect on Congestion and renal funcTion) trial. Rolofylline 30 mg or matching placebo was given intravenously as a 4-hour continuous infusion on 3 consecutive days and the hospital course was assessed by measurements dyspnea, clinical status, renal function, and subsequent morbidity and mortality in a large population of patients with ADHF with renal impairment.